Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,,,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,,,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,,,Disease
compared tothe risk profile of the patients in the ARTS I Study./p... Patients with multivessel disease and diabetes represent someof th...After three years of follow-up the overall patient populationtreat... Close to 30 years ago balloon angioplasty transformed thetreatmen...The ARTS II Study investigators also reported stent thrombosisrates...
compared to
the risk profile of the patients in the ARTS I Study.
"Patients with multivessel disease and diabetes represent some
of the most complex cases to treat," said Keith D Dawkins, M.D.,
F.R.C.P., F.A.C.C., from Southampton University Hospital, who
presented the analysis at EuroPCR 2007. "These findings suggest
that the CYPHER(R) Stent may be a viable, less invasive treatment
alternative for these very challenging cases."
After three years of follow-up, the overall patient population
treated with the CYPHER(R) Stent in the ARTS II Study also
continued to show similar rates of freedom from MACCE than the
patients treated with bypass surgery in the ARTS I Study.
Specifically, 80.6 percent of the overall patient population who
received the CYPHER(R) Stent remained free of MACCE, compared to
83.8 percent of the patients who underwent bypass surgery.
Additionally, the CYPHER(R) Stent performed considerably better
than the ARTS I BMS arm in the same endpoint, as 66.0 percent of
the patients who received a BMS did not experience a MACCE event
after three years. The difference between the CYPHER(R) Stent arm
and the BMS arm reached statistical significance (p <
0.001).
"Close to 30 years ago, balloon angioplasty transformed the
treatment paradigm for patients with coronary artery disease," said
David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical
Officer, Cordis Cardiology Division of Cordis Corporation. "This
three-year analysis suggests that balloon angioplasty combined with
the CYPHER(R) Stent may be a viable alternative to bypass surgery
for non-diabetic and diabetic patients with multivessel coronary
disease."
The ARTS II Study investigators also reported stent thrombosis
rates using the Academic Research Consortium (ARC) definition. The
definite stent thrombosis rate for the CYPHER(R) Stent in the
diabetic patient population 30 days after implantation was
signi
'"/>
Page: 1 2 3 4 Related medicine technology :1.
Cypher Sirolimus-eluting Coronary Stent Had Similar Results to
Bypass Surgery in Long-Term Study of Patients With Multi-Vessel
Coronary Artery Disease2.
Two-Year Patient Registry Results Support Safety and Efficacy of
Cypher Sirolimus-Eluting Coronary Stent in Real World Uses3.
New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings4.
New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk5.
BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease6.
BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease7.
Lipitor Reduced the Risk of Coronary Events by Half and Stroke by
Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who
Experienced a Recent Stroke8.
New Analysis of WHI Data Shows Reduced Levels of Coronary Artery
Calcification, a Predictor of Cardiovascular Events, in Women aged
50-59 taking Estrogen Therapy9.
Positive Results for Second-Generation Taxus Liberte Coronary Stent
System Highlighted in Journal of American College of Cardiology10.
Abbott Announces Positive Nine-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent11.
Abbott Announces Continued Positive Results with Xience V
Everolimus Eluting Coronary Stent in Spirit Clinical Trials
(Date:10/9/2008)...rstCall/ -- Diamyd Medical reports,that the world,...d Journal,of Medicine, has published an article wi...R) diabetes vaccine for type 1 diabetes., (Logo: ...94 ), The article is now available on the journa...n print on October 30. It presents the,results of ...
(Date:10/8/2008)...ntinued and Headcount to be Reduced, Summary: Genm...Zanolimumab Program to be Discontinued and the Co... Employees, COPENHAGEN, October 8 /PRN...ced today that it is discontinuing development of ...lt of a portfolio review and,assessment of the org...
(Date:10/8/2008)... improvement in patients with pulmonary arter...tions have limited benefit for this debilitating, ...l disease, -- Imatinib mesylate, available as G...nown to inhibit protein associated with PAH, -- ... mesylate in PAH in 2009 EAST HANOVER, N.J.,...
(Date:10/7/2008)... the Osteoarthritis Research Society,International.../- Ferring Pharmaceuticals Inc.,recen...oarthritis of the,Knee, showing that EUFLEXXA(R) (...gh molecular weight form of intra-articular hyalur...saline (IA-saline) for the relief,of pain in knee ...
Breaking Medicine Technology:Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 1KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 2KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 3KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 4KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 5KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 6KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 7KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 8KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 9KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 10KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 11KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 12KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 13KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results 25301 14AMA Foundation Presents 2410 000 Scholarships to Promising Medical Students 25298 1AMA Foundation Presents 2410 000 Scholarships to Promising Medical Students 25298 2AUDIO from Medialink and Pfizer 3A Community Health Centers Celebrated for Making Quality Care Available to Uninsured Americans 25295 1VirtualScopics Receives NASDAQ Delisting Notice 3B Company Files Appeal to Stay Delisting 25290 1VirtualScopics Receives NASDAQ Delisting Notice 3B Company Files Appeal to Stay Delisting 25290 2VirtualScopics Receives NASDAQ Delisting Notice 3B Company Files Appeal to Stay Delisting 25290 3...)--Jun 13, 2007 - EPIX,Pharmaceuticals, Inc. (NASD... 3 trial of PRX-00023, a novel long-acting 5-HT1A ...the 47th Annual New,Clinical Drug Evaluation Unit ...g is sponsored by the National Institutes of,Healt...acology., The presentation highlighted data from a...
...WIRE)--Jun 14, 2007 - Can-Fite,BioPharma (TASE:CFB... Stock Exchange Exchange, proceeds with the develo... to CF101, which is currently,in clinical trials a...kend Can-Fite will present at the EUALR annual con...esults showing effective,anti-inflammatory activit...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2...f that only bad dogs bite, it has been found that ... argue pediatricians//. Doesn’t sound alarming? Ac...erican Academy of Paediatrics (AAP), dogs bite nea... More than half of all these victims are younger t...
...awaharlal Institute of Post-graduate Medical Educa... chain agitation’// to protest the move to reserve...ons. Students of the Central government-administe...ally inside the Institute's premises before organi...
...vegan women's levels of IGF are lower than those o...twin production is higher in countries that consum... Haggerty who studies nutrition, fertility and dis... Aberdeen, UK, was quoted by Nature as saying. Bu...
...Nadu and their support groups have planned to orga...e UN towards non-implementation// of the recommend...(UNGASS) to address the problem of HIV/AIDS. Esth...f ActionAid, told reporters here that UNGASS in 20...
Other Medicine News:Health News:Watch Out! Even Good Dogs Can Bite Your Kids 2Flattened Blunt Tip, Angled; 13mm from angle to tip; 3mm "U" shape tip; overall length excluding hub 28mm; in stainless steel.
Set of Five, Long, with side port; all approximately 75mm in length; in Stainless Steel.
HYDRACLEAR is our brandname for a remarkable moisture rich element that lies throughout the interior and exterior of the ACUVUE ADVANCE Brand Contact Lenses creating a unique soft, silky feel.
The only solution for in-line digital measurement
Medicine Products: